- Home
- RCON vs MCRB Comparison
RCON vs MCRB Comparison
Compare RCON & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCON
- MCRB
- Stock Information
- Founded
- RCON 2007
- MCRB 2010
- Country
- RCON China
- MCRB United States
- Employees
- RCON N/A
- MCRB N/A
- Industry
- RCON Oilfield Services/Equipment
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- RCON Energy
- MCRB Health Care
- Exchange
- RCON Nasdaq
- MCRB Nasdaq
- Market Cap
- RCON 60.5M
- MCRB 72.0M
- IPO Year
- RCON 2009
- MCRB 2015
- Fundamental
- Price
- RCON $2.75
- MCRB $7.63
- Analyst Decision
- RCON
- MCRB Hold
- Analyst Count
- RCON 0
- MCRB 4
- Target Price
- RCON N/A
- MCRB $73.67
- AVG Volume (30 Days)
- RCON 297.8K
- MCRB 75.0K
- Earning Date
- RCON 07-01-2025
- MCRB 08-12-2025
- Dividend Yield
- RCON N/A
- MCRB N/A
- EPS Growth
- RCON N/A
- MCRB N/A
- EPS
- RCON N/A
- MCRB 8.98
- Revenue
- RCON $8,996,572.00
- MCRB N/A
- Revenue This Year
- RCON N/A
- MCRB N/A
- Revenue Next Year
- RCON $12.17
- MCRB N/A
- P/E Ratio
- RCON N/A
- MCRB $0.89
- Revenue Growth
- RCON N/A
- MCRB N/A
- 52 Week Low
- RCON $1.33
- MCRB $6.53
- 52 Week High
- RCON $3.70
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- RCON 61.06
- MCRB 48.66
- Support Level
- RCON $2.00
- MCRB $7.25
- Resistance Level
- RCON $2.99
- MCRB $7.89
- Average True Range (ATR)
- RCON 0.26
- MCRB 0.46
- MACD
- RCON 0.03
- MCRB 0.11
- Stochastic Oscillator
- RCON 63.58
- MCRB 60.23
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.